Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

A Phase IIa Trial of the Oral JAK 1/2 Inhibitor, Baricitinib, in the Treatment of Adult IIM (MYOJAK)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04208464
Recruitment Status : Not yet recruiting
First Posted : December 23, 2019
Last Update Posted : December 23, 2019
Eli Lilly and Company
Manchester Clinical Trials Unit
Karolinska Institutet
Information provided by (Responsible Party):
Hector Chinoy, University of Manchester

No Study Results Posted on for this Study
Recruitment Status : Not yet recruiting
Estimated Primary Completion Date : February 28, 2022
Estimated Study Completion Date : February 28, 2022